| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Neurosciences: NeurologyNeurology Posters |
1 Nuclear Medicine; ; 2 Neurology, University of Sassari, Sassari, Italy
951
Objectives: Conflicting data exist proving GSH treatment effect on dopamine transporter (DAT) in PD pts, since drug ability in crossing blood brain barrier (BBB) is still debated. We further investigated potential GSH effect on DAT in PD pts treated or not with antiparkinsonian drugs.
Methods: Twenty pts with idiopathic PD, 11 treated with antiparkinsonian drugs and 9 never treated, and 8 healthy subjects ( C ) underwent to 123I-Ioflupane SPECT (148 MBq i.v.), PD pts twice, at baseline and within 0.5-2 months after intramuscular GSH therapy 600 mg twice daily, with treated pts maintaining basal therapy. SPECT was evaluated both qualitatively and semiquantitatively calculating putamen/occipital (p/o) and caudate/occipital (c/o) ratios. Total Unified PD rating scale (UPDRS) was performed before SPECT.
Results: At basal SPECT, in 35/40 involved putamen, 20 of which in treated and 15 in never treated pts, p/o was reduced with mean values significantly (p<0.0000001) lower than 5/40 not involved putamen and the 16 C putamen with no difference between the two latter groups; c/o was normal in all cases. After GSH therapy, in 25/35 (71.4%) involved putamen p/o increased, with a percentage increment >30% in 11/25 cases, p/o mean values being significantly (p<0.0009) higher than basal values, with the highest increment value frequency in never treated pts (40%) than treated cases (15%). In the remaining 10/35 involved putamen p/o had no change (8 cases) or negative response (2 cases). UPDRS slightly increased in 9 pts.
Conclusions: Our data seems to evidence BBB penetration by GSH which may increase putamen DAT binding in PD pts, particularly in never treated cases in our series. A potential therapeutic GSH role may also be suggested.
| ||||||||||||||||||||||||||||
